guidelines:
  1: ACC-AHA_Heart_Failure_Staging.v1
test_cases:
- id: Stage 0
  input:
    1:
      gt0004|Q1.Patient with history of hypertension, coronary artery disease, OR diabetes (If yes go to Q4): 0|local::at0005|No|
      gt0005|Q2.Patient using cardiotoxins: 0|local::at0009|No|
      gt0006|Q3.Patient with family history of cardiomyopathy: 0|local::at0013|No|
      gt0007|Q4.Patient with previous MI, LV systolic dysfunction, or asymptomatic valvular disease(If yes go to Q5): 0|local::at0020|No|
      ? gt0008|Q5.Patient with known structural heart disease, shortness of breath
        and fatigue(Reduced exercise tolerance) (If yes go to Q6)
      : 0|local::at0023|No|
      ? gt0009|Q6.Patient with marked heart failure symptoms at rest, despite maximum
        therapy(Those who are recurrently hospitalized or cannot be safely discharged
        from the hospital without specialized intervention.)
      : 0|local::at0026|No|
  expected_output:
    1:
      gt0010|Stage: 0|local::at0031|Patient does not have substantial risk of HF based ACC AHA staging guidelines.|
      gt0017|Management: 0|local::at0009|Patient does not have substantial risk of HF based ACC/AHA staging guidelines.|


- id: Stage A
  input:
    1:
      gt0004|Q1.Patient with history of hypertension, coronary artery disease, OR diabetes (If yes go to Q4): 1|local::at0006|Yes|
      gt0005|Q2.Patient using cardiotoxins: 0|local::at0009|No|
      gt0006|Q3.Patient with family history of cardiomyopathy: 0|local::at0013|No|
      gt0007|Q4.Patient with previous MI, LV systolic dysfunction, or asymptomatic valvular disease(If yes go to Q5): 0|local::at0020|No|
      ? gt0008|Q5.Patient with known structural heart disease, shortness of breath
        and fatigue(Reduced exercise tolerance) (If yes go to Q6)
      : 0|local::at0023|No|
      ? gt0009|Q6.Patient with marked heart failure symptoms at rest, despite maximum
        therapy(Those who are recurrently hospitalized or cannot be safely discharged
        from the hospital without specialized intervention.)
      : 0|local::at0026|No|
  expected_output:
    1:
      gt0010|Stage: 1|local::at0032|A- High risk for developing HF but no structural disorder of the heart|
      gt0017|Management: 1|local::at0010|Therapy considerations:Treat hypertension;Encourage smoking cessation;Treat lipid disorders;Encourage regular exercise;Discourage alcohol intake/illicit drug use;ACE inhibitors in appropriate patients.|


- id: Stage B
  input:
    1:
      gt0004|Q1.Patient with history of hypertension, coronary artery disease, OR diabetes (If yes go to Q4): 1|local::at0006|Yes|
      gt0005|Q2.Patient using cardiotoxins: 1|local::at0010|Yes|
      gt0006|Q3.Patient with family history of cardiomyopathy: 1|local::at0014|Yes|
      gt0007|Q4.Patient with previous MI, LV systolic dysfunction, or asymptomatic valvular disease(If yes go to Q5): 1|local::at0021|Yes|
      ? gt0008|Q5.Patient with known structural heart disease, shortness of breath
        and fatigue(Reduced exercise tolerance) (If yes go to Q6)
      : 0|local::at0023|No|
      ? gt0009|Q6.Patient with marked heart failure symptoms at rest, despite maximum
        therapy(Those who are recurrently hospitalized or cannot be safely discharged
        from the hospital without specialized intervention.)
      : 0|local::at0026|No|
  expected_output:
    1:
      gt0010|Stage: 2|local::at0033|B-Structural disorder of the heart but has never developed symptoms of HF|
      gt0017|Management: 2|local::at0011|All measures under stage A;ACE inhibitors in appropriate patients;Beta-blockers in appropriate patients.|

- id: Stage C
  input:
    1:
      gt0004|Q1.Patient with history of hypertension, coronary artery disease, OR diabetes (If yes go to Q4): 1|local::at0006|Yes|
      gt0005|Q2.Patient using cardiotoxins: 0|local::at0009|No|
      gt0006|Q3.Patient with family history of cardiomyopathy: 0|local::at0013|No|
      gt0007|Q4.Patient with previous MI, LV systolic dysfunction, or asymptomatic valvular disease(If yes go to Q5): 1|local::at0021|Yes|
      ? gt0008|Q5.Patient with known structural heart disease, shortness of breath
        and fatigue(Reduced exercise tolerance) (If yes go to Q6)
      : 1|local::at0024|Yes|
      ? gt0009|Q6.Patient with marked heart failure symptoms at rest, despite maximum
        therapy(Those who are recurrently hospitalized or cannot be safely discharged
        from the hospital without specialized intervention.)
      : 0|local::at0026|No|
  expected_output:
    1:
      gt0010|Stage: 3|local::at0034|C-Past or current symptoms of HF associated with underlying structural heart disease|
      gt0017|Management: 3|local::at0012|All measures under stage A;Diuretics, ACE inhibitors, beta-blockers, or digitalis for routine use; Dietary salt restriction.|


- id: Stage D
  input:
    1:
      gt0004|Q1.Patient with history of hypertension, coronary artery disease, OR diabetes (If yes go to Q4): 1|local::at0006|Yes|
      gt0005|Q2.Patient using cardiotoxins: 0|local::at0009|No|
      gt0006|Q3.Patient with family history of cardiomyopathy: 0|local::at0013|No|
      gt0007|Q4.Patient with previous MI, LV systolic dysfunction, or asymptomatic valvular disease(If yes go to Q5): 1|local::at0021|Yes|
      ? gt0008|Q5.Patient with known structural heart disease, shortness of breath
        and fatigue(Reduced exercise tolerance) (If yes go to Q6)
      : 1|local::at0024|Yes|
      ? gt0009|Q6.Patient with marked heart failure symptoms at rest, despite maximum
        therapy(Those who are recurrently hospitalized or cannot be safely discharged
        from the hospital without specialized intervention.)
      : 1|local::at0027|Yes|
  expected_output:
    1:
      gt0010|Stage: 4|local::at0035|D-End-stage disease requiring specialized treatment strategies such as mechanical circulatory support, continuous inotropic infusions, cardiac transplantation, or hospice care.|

      gt0017|Management: 4|local::at0013|All measures under stage A, B and C; Mechanical assist devices; Heart transplantation; Continuous IV inotropic infusions for palliation; Hospice care.|



